Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the feasibility of utilizing a reduced intensity conditioning regimen,
in the setting of haploidentical transplantation, for patients with recurrent acute
lymphoblastic leukemia (ALL), AML and high risk or refractory solid tumors. In addition, the
feasibility and safety of administering post-transplant NK cell infusions will be evaluated.
Data obtained from this study will help determine the efficacy of allogeneic HSCT in the
treatment of pediatric sarcomas and add to the small body of literature utilizing
haploidentical HSCT to treat acute leukemia in pediatric patients. This study will also
further elucidate the role of NK cells in mediating a graft vs. tumor effect in allogeneic
HSCT. The main benefit to society is that this study will explore a novel therapy for
children with highly refractory cancer who are felt to be incurable with conventional
approaches. If feasibility is demonstrated, and there is evidence of anti-tumor activity,
then this will open up a new area of clinical research to better define the efficacy of this
approach for specific childhood malignancies.